City Therapeutics, Inc. (CTY)
NASDAQ: CTY · Real-Time Price · USD
18.17
+1.10 (6.44%)
Nov 6, 2026, 3:04 PM EST - Market open
City Therapeutics Revenue
City Therapeutics had revenue of $3.18M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $14.34M. In the year 2025, City Therapeutics had annual revenue of $13.56M with 388.19% growth. That makes City Therapeutics the 35,650th largest company in the world by revenue and 4,687th in the United States.
Revenue (ttm)
$14.34M
Revenue Growth
+388.19%
P/S Ratio
61.51
Revenue / Employee
$191,227
Employees
75
Market Cap
904.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.56M | 10.78M | 388.19% |
| Dec 31, 2024 | 2.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
CTY News
- 2 days ago - Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting - GlobeNewsWire
- 3 days ago - City Therapeutics to Present at Upcoming November Investor Conferences - GlobeNewsWire
- 13 days ago - Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere - Barrons
- 18 days ago - City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 18 days ago - Opening Day: Biotech duo City Therapeutics, Iambic make debuts - TheFly
- 21 days ago - City Therapeutics opened at $23, IPO priced at $18 per share - TheFly
- 21 days ago - City Therapeutics indicated to open at $22, IPO priced at $18 - TheFly
- 21 days ago - City Therapeutics indicated to open at $20.25, IPO priced at $18 - TheFly